+44 (0) 1793 575 050
customerservice@regenmedical.co.uk

Part of the Joint Operations family

This early case series from the Welsh Wound Innovation Centre looks at some of the first patients in the UK to receive EpiFix®, our amniotic tissue for use in acute and chronic wounds.

This early data looks at a range of patients with wounds spanning 6 months, 12 months, 2 years and 9 years over a period of 5, 8 and 12 weeks.

Welsh Wound Innovation Centre

The Welsh Wound Innovation Centre (WWIC) is the world’s first national wound healing centre and is the flagship facility for clinical innovation in Wales. The WWIC plays a vital role in Wales’ economic development, helping to accelerate growth by stimulating and supporting business-led innovation in wound care.

You can find out more about the WWIC here

See the latest:

Level 1 Evidence EpiFix Published Study

EPIFIX® DEMONSTRATES SUPERIOR HEALING RATES IN DFUs vs. SOC

In a recently published Level 1 study examining the efficacy of EpiFix in conjunction with Standard of Care (SOC) for the treatment of diabetic foot ulcers (DFUs), it was reported that EpiFix demonstrates higher healing rates with a superior wound healing trajectory in a heterogeneous patient population compared to SOC alone (control).

CLICK HERE TO READ THE STUDY IN FULL

1. Tettelbach W, Cazzell S, Reyzelman AM, Sigal F, Caporusso JM, Agnew PS. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. Int Wound J. 2018;1–11.